US Patent 11926668 Anti-PD-1 antibodies for treatment of lung cancer
Patent 11926668 was granted and assigned to Regeneron Pharmaceuticals on March, 2024 by the United States Patent and Trademark Office.
All edits
Edits on 14 Mar, 2024
Golden AI
Edits made to:
Infobox (+19 properties)
Article (+387 characters)
US Patent 11926668 Anti-PD-1 antibodies for treatment of lung cancer
Article
Patent abstract
The present invention provides methods for treating, reducing the severity, or inhibiting the growth of cancer (e.g., lung cancer). The methods of the present invention comprise administering a therapeutically effective amount of a programmed death 1 (PD-1) antagonist (e.g., an anti-PD-1 antibody), to a subject with lung cancer wherein the cancer tissue expresses PD-L1.
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
Patent Inventor Names
Israel Lowy0
Petra Rietschel0
Date of Patent
March 12, 2024
0Patent Application Number
176527090
Date Filed
February 28, 2022
0Patent Citations
Patent Primary Examiner
CPC Code
Find more entities like US Patent 11926668 Anti-PD-1 antibodies for treatment of lung cancer
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
